You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: December 22, 2024

Details for Patent: 5,817,028


✉ Email this page to a colleague

« Back to Dashboard


Summary for Patent: 5,817,028
Title: Method and device for the provocation of air passage narrowing and/or the induction of sputum
Abstract:A method as described for testing the susceptibility of a person to asthma. The person inhales an effective amount of sodium chloride, mannitol or another substance capable of altering the osmolarity of airway surface liquid in the subject. The substance is in the form of a dispersible dry powder containing an effective proportion of particles of a respirable size. The subject is then measured to detect airway narrowing which is indicative of a propensity for asthma. The same technique of dry powder inhalation can be used to test for the susceptibility of a person to rhinitus, to induce sputum and promote mucociliary clearance.
Inventor(s): Anderson; Sandra Doreen (Birchgrove, AU)
Assignee: Central Sydney Area Health Service (Camperdown, AU)
Application Number:08/696,987
Patent Claim Types:
see list of patent claims
Use; Dosage form;
Patent landscape, scope, and claims:

Understanding the Scope and Claims of U.S. Patents: A Detailed Analysis

Introduction

The U.S. patent system, managed by the U.S. Patent and Trademark Office (USPTO), is a complex and evolving field that plays a crucial role in innovation and technological advancement. This article will delve into the scope and claims of U.S. patents, using the recent 2024 USPTO guidance update on AI patents as a framework, and provide insights into the patent landscape.

The Role of the USPTO

The USPTO is the agency responsible for granting U.S. patents and registering trademarks. It ensures that inventions meet the criteria for patentability, which includes novelty, non-obviousness, and usefulness[2].

Patent Eligibility Criteria

Patent eligibility is a critical aspect of the patent process. The 2024 USPTO guidance update, prompted by Executive Order 14110, aims to clarify the process for determining the patent eligibility of AI-related inventions. Here are the key takeaways:

Evaluating Judicial Exceptions

The update emphasizes evaluating whether a claim integrates a judicial exception into a practical application. This involves assessing additional elements in the claim to determine if they impose meaningful limits on the exception, transforming the claim into patent-eligible subject matter[1].

AI-Assisted Inventions

The guidance clarifies that the method of invention development, including the use of AI, does not impact subject matter eligibility. Instead, the focus remains on the claimed invention itself, ensuring that AI-assisted inventions are evaluated on equal footing with other technologies[1].

Practical Applications

Highlighting the real-world applications of the claimed method or system is crucial. Demonstrating how the abstract idea is applied in a way that provides concrete benefits or solves specific problems in the relevant field is essential for patent eligibility[1].

Example Analysis: Claim 1 vs. Claim 2

To illustrate the difference, consider two claims:

  • Claim 1: This claim merely uses a mathematical model to manipulate data without applying the data in any specific manner that improves technology or provides a practical application. It is considered ineligible because it does not integrate the abstract idea into a practical application.
  • Claim 2: This claim specifies the use of separated audio components in a real-time speech recognition system to enhance the accuracy of voice commands in hands-free environments. This claim is eligible because it includes a practical application that provides clear benefits, such as improved accuracy in speech recognition systems[1].

Patent Claims Research Dataset

The USPTO provides extensive datasets on patent claims, which can be used to analyze trends and patterns in patenting. The Patent Claims Research Dataset contains detailed information on claims from U.S. patents granted between 1976 and 2014 and U.S. patent applications published between 2001 and 2014. This dataset helps in understanding the scope and complexity of patent claims over time[3].

Trends in Patent Activity

The USPTO awarded 309,000 utility patents in 2018, with a significant portion going to businesses. Electrical and mechanical engineering patents made up about 60% of the patents granted to U.S. inventors in 2018. The role of information and communication technologies (ICT) is also evident, with computer technology and digital communication driving the increase in electrical engineering patents[4].

Small Claims Patent Court

There has been ongoing discussion about the feasibility of a small claims patent court. The Administrative Conference of the United States (ACUS) conducted a study on this topic, engaging with a wide range of stakeholders to address the need, feasibility, and potential structure of such a court. This initiative aims to make the patent litigation process more accessible and efficient for smaller entities[5].

Case Study: U.S. Patent 5,817,028

While the specific details of U.S. Patent 5,817,028 are not provided here, the general principles outlined above can be applied to understand its scope and claims.

Claim Structure

To analyze the claims of U.S. Patent 5,817,028, one would need to examine the claim structure, focusing on whether the claims integrate abstract ideas into practical applications. Each claim should be evaluated for its specificity, practical utility, and the presence of meaningful limits on any judicial exceptions.

Practical Applications

The patent's claims should demonstrate how the invention is applied in a real-world setting, providing concrete benefits or solving specific problems. This could involve detailing the use of the invention in a particular industry or application, similar to the example of Claim 2 in the 2024 USPTO guidance update.

Industry Relevance

Understanding the industry context in which the patent operates is crucial. For instance, if the patent is related to electrical engineering or ICT, it would be important to see how it fits into the broader trends and advancements in these fields.

Key Takeaways

  • Patent Eligibility: The 2024 USPTO guidance update emphasizes the integration of judicial exceptions into practical applications and the equal treatment of AI-assisted inventions.
  • Claim Structure: Claims must be specific, provide practical utility, and impose meaningful limits on judicial exceptions.
  • Industry Trends: Patents are often part of larger industry trends, such as the growth in ICT and electrical engineering patents.
  • Access to Justice: Initiatives like the small claims patent court aim to make patent litigation more accessible.

FAQs

What is the main focus of the 2024 USPTO guidance update on AI patents?

The main focus is on refining and clarifying the process for determining the patent eligibility of AI-related inventions, particularly by evaluating whether claims integrate judicial exceptions into practical applications.

How does the use of AI affect patent eligibility?

The use of AI in the development of an invention does not impact subject matter eligibility. The focus remains on the claimed invention itself, ensuring AI-assisted inventions are evaluated equally with other technologies.

What makes a claim patent-eligible according to the 2024 USPTO guidance?

A claim is patent-eligible if it integrates a judicial exception into a practical application, providing meaningful limits on the exception and demonstrating concrete technological improvements.

What is the significance of the Patent Claims Research Dataset?

The dataset provides detailed information on claims from U.S. patents and applications, helping to analyze trends and patterns in patenting and understand the scope and complexity of patent claims.

Why is there a discussion about a small claims patent court?

The discussion aims to make the patent litigation process more accessible and efficient for smaller entities, addressing the need, feasibility, and potential structure of such a court.

Sources

  1. Understanding the 2024 USPTO Guidance Update on AI Patent - Mintz
  2. U.S. Patent and Trademark Office (USPTO) | USAGov
  3. Patent Claims Research Dataset - USPTO
  4. Invention: U.S. and Comparative Global Trends - NCSES
  5. U.S. Patent Small Claims Court - ACUS

More… ↓

⤷  Subscribe


Drugs Protected by US Patent 5,817,028

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Submissiondate
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Patented / Exclusive Use >Submissiondate

Foreign Priority and PCT Information for Patent: 5,817,028

Foriegn Application Priority Data
Foreign Country Foreign Patent Number Foreign Patent Date
AustraliaPM4114Feb 25, 1994
PCT Information
PCT FiledFebruary 23, 1995PCT Application Number:PCT/AU95/00086
PCT Publication Date:August 31, 1995PCT Publication Number: WO95/22993

International Family Members for US Patent 5,817,028

Country Patent Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
European Patent Office 0748228 ⤷  Subscribe 11C0002 France ⤷  Subscribe
European Patent Office 0748228 ⤷  Subscribe SPC/GB11/004 United Kingdom ⤷  Subscribe
Austria 474583 ⤷  Subscribe
Australia 1748295 ⤷  Subscribe
Australia 682756 ⤷  Subscribe
>Country >Patent Number >Estimated Expiration >Supplementary Protection Certificate >SPC Country >SPC Expiration

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.